View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
June 28, 2019

Mantle cell lymphoma: BTK inhibitors have the highest commercial potential

The mantle cell lymphoma (MCL) landscape is diverse, containing nine drugs that are aimed at a variety of targets, including CD20, Bruton’s tyrosine kinase (BTK), DNA, 26s proteasome, and phosphoinositide 3-kinase (PI3K).

By GlobalData Healthcare

The mantle cell lymphoma (MCL) landscape is diverse, containing nine drugs that are aimed at a variety of targets, including CD20, Bruton’s tyrosine kinase (BTK), DNA, 26s proteasome, and phosphoinositide 3-kinase (PI3K).

The figure below displays a competitive assessment of the marketed and late-stage pipeline drugs for MCL, a sub-type of non-Hodgkin’s lymphoma. The drugs are scored according to their clinical and commercial attractiveness.

Roche’s Rituxan (rituximab), with or without chemotherapy, is the standard-of-care regimen against which other agents are compared. While Rituxan possesses the highest clinical efficacy, it no longer possesses the highest commercial potential, as there are now rituximab biosimilars available in the US, the five major European markets (5EU: France, Germany, Italy, Spain, and the UK), and Japan.

Competitive assessment of MCL drugs 

Mantle cell lymphoma therapies

Source: GlobalData. © GlobalData

The therapies with the highest commercial potential in MCL are BTK inhibitors: AbbVie and Johnson & Johnson’s (J&J’s) Imbruvica (ibrutinib) and AstraZeneca’s Calquence (acalabrutinib), which have demonstrated high efficacy in MCL.

Other agents, including Celgene’s Revlimid (lenalidomide), Teva’s Treanda (bendamustine), Takeda’s Velcade (bortezomib), TG Therapeutics’ pipeline agents ublituximab and umbralisib (also known as the U2 regimen), and AbbVie’s Venclexta (venetoclax tablets), rank similarly in terms of commercial and clinical attributes. The outlier is Pfizer’s Torisel (temsirolimus), which has not demonstrated much efficacy in MCL and is not approved for that indication in the US.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology